Raymond James 分析师近日发布研报,首次覆盖生物技术公司 MapLight Therapeutics,并给予其“强力买入”评级。报告同时为该股设定了46美元的目标价,显示出对该司未来前景的强烈信心。
Raymond James 分析师近日发布研报,首次覆盖生物技术公司 MapLight Therapeutics,并给予其“强力买入”评级。报告同时为该股设定了46美元的目标价,显示出对该司未来前景的强烈信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.